É. Luporsi

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Hervé Bonnefoi, Saskia Litière, Martine Piccart et al. · Annals of Oncology · 2014 · 197 citations · Full text

Breast Oncology, Eortc 10994/Big, Medicine +7

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results

P. Fumoleau, Henri Roché, Pierre Kerbrat et al. · Annals of Oncology · 2005 · 108 citations · Full text

Adjuvant Epirubicin-based Chemotherapy, Breast Oncology, Oncology +9

High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: Final results of a phase II study

D. Peiffert, Marc Giovannini, Michel Ducreux et al. · Annals of Oncology · 2001 · 99 citations · Full text

Surgical Oncology, High-dose Radiation Therapy, Radiation Therapy +8

French version of FACT-G: validation and comparison with other cancer-specific instruments

Thierry Conroy, M. Mercier, Jacques Bonneterre et al. · European Journal of Cancer · 2004 · 78 citations

Surgical Oncology, French Version, Medicine +9